KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics, Inc.

  • KaliVir Immunotherapeutics, Inc. just raised $14M (Series A Extension) on Aug 19

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

2019Active29Pittsburgh, United States
5.0 (1)

About

KaliVir Immunotherapeutics is a clinical-stage biotechnology company focused on developing innovative, multi-mechanistic oncolytic immunotherapy programs. The company leverages its proprietary Vaccinia Enhanced Template (VET™) platform to engineer vaccinia viruses that selectively replicate in and kill cancer cells, while also stimulating anti-tumor immunity and modifying the tumor microenvironment. Their product candidates are designed for systemic intravenous delivery to treat various cancer types.

Signals agent

Reach companies that have budget right now

Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.

  • Just raised a roundFresh budget, the week it lands
  • Hiring sales and marketingGo-to-market roles mean money to spend
  • Hiring fastA jump in open roles across the company
  • In the newsLaunches and announcements worth a message
  • The decision makerWho to contact, with a message you can edit

Is your startup an alternative to KaliVir Immunotherapeutics, Inc.?

People comparing tools land here. Get listed beside these.

Copy KaliVir Immunotherapeutics, Inc.'s SEO strategy

How often they publish, which searches their posts chase and their newest posts. Then outrank them.

All funding rounds

Key facts

Website
kalivir.com
Headquarters
Pittsburgh, United States
Founded
2019
Employees
29
Total funding
$14M (Series A Extension)
Business model
B2B

Funding rounds

Funding rounds raised by KaliVir Immunotherapeutics, Inc.
DateRoundAmountLead investors
19 Aug 2026Series A Extension$14MCompany K Partners

Tech stack

Detected on kalivir.com, last scanned 4 Nov 2026.

Frontend
jQuery
SEO
All in One SEO
CMS / Builders
WordPress
CDN
Cloudflare
Email provider
Microsoft 365

Benchmarking

See how your site ranks against 16,849 startups

KaliVir Immunotherapeutics, Inc. sits in the 17th percentile for Domain Rating. Check where yours lands, free.

KaliVir Immunotherapeutics, Inc. has a Domain Rating of 10, the 17th percentile of 16,849 startups we track.

Scores

Measured, not editorial

10

Measured by AhrefsAhrefs DR

Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.

Bottom 25%

Check yours
9

Measured by StartupHub.aiEffective DR

Our own read on real cross-surface visibility rather than raw backlink authority. A site can carry a high Domain Rating and still be invisible where people actually look, which is what this measures.

Bottom 25%

Check yours
45

Measured by StartupHub.aiAgent Readiness

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Above median

Scan yours
56

Measured by Google PageSpeedSite Speed

Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.

Below median

PageSpeed
76

Measured by StartupHub.aiData Trust

Whether this company is a safe place to put your data: security posture, privacy signals, and reputation evidence we could verify.

Above median

Measured by StartupHub.aiSecurity

What this company’s API or MCP server gives an anonymous stranger: transport, whether anything answers without credentials, CORS, response headers and, when an MCP server replies, which of its tools can be called with no key. Scanned live, on request, because a security verdict months old is worse than none.

Click to scan

Agent Readiness

Can AI agents use your site?

KaliVir Immunotherapeutics, Inc. scores 45. Check yours free in a few seconds, or let Max Agent rerun it daily.

Run it daily with Max Agent
Median 41Across 23,755 scanned sites

Get notified when KaliVir Immunotherapeutics, Inc. changes

Used KaliVir Immunotherapeutics, Inc.? Write a review and get $5 in credits

Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:

  • Email finder
  • Market Map Maker
  • Agent Readiness scans
  • Deep intel
  • Tech stack scans

Frequently asked

Is KaliVir Immunotherapeutics, Inc. growing?

Yes, fast. Our data shows it raised $14M in a Series A Extension in August 2026.

Who owns KaliVir Immunotherapeutics, Inc.?

KaliVir Immunotherapeutics, Inc. is privately held, owned by its founders and investors. Investors on record include Company K Partners, SV Investment, Flexus Partners and Nextrans. Exact stakes are not public.

Are there companies like KaliVir Immunotherapeutics, Inc.?

Yes. We list 6 companies like KaliVir Immunotherapeutics, Inc., including Moderna, BioNTech and Epicrispr Biotechnologies.

What is KaliVir Immunotherapeutics, Inc.'s Effective Domain Rating?

StartupHub's Effective Domain Rating for KaliVir Immunotherapeutics, Inc. is 9 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is fairly rated against its Ahrefs Domain Rating of 10.

Is KaliVir Immunotherapeutics, Inc. trustworthy and reputable?

StartupHub's Data Trust & Reputation score for KaliVir Immunotherapeutics, Inc. is 76 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has KaliVir Immunotherapeutics, Inc. raised?

KaliVir Immunotherapeutics, Inc. has raised a total of $14M in funding. The most recent round on record is Series A Extension.

How many employees does KaliVir Immunotherapeutics, Inc. have?

KaliVir Immunotherapeutics, Inc. has approximately 29 people on record.

SEC filings, insider activity, nonprofit links and pay benchmarks for KaliVir Immunotherapeutics, Inc.:

Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules

Categories

Need more than this profile? Deep intel researches any company website: team, funding, customers and tech.

Max Agent

Let Max Agent watch KaliVir Immunotherapeutics, Inc. and its market for you

New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.

Free week

Starter listings, once

AI answers checked

Daily for 7 days

  • ChatGPT
  • Perplexity

Max Agent

$79 a month, or $9.99 with our badge on your site

AI answers checked

Every week

  • ChatGPT
  • Claude
  • Perplexity
  • Gemini